Skip to Main Content

Advertisement

Skip Nav Destination

Issues

Journal Archive

Cancer Immunology Research (2013-Present)

(ISSN 2326-6066) Published monthly since 2013.

Cancer Immunity (2001-2013; volumes 1-13)

(EISSN 1424-9634) Published periodically from 2001-2013.

Table of Contents

What We're Reading

Review

Priority Brief

Greater understanding of immune-related adverse events (irAE) could lead to new approaches in overcoming them. The authors show immunopathology of irAE dermatitis is dominated by Th1/Tc1 TRM cells, suggesting topical JAK inhibitors as corticosteroid-sparing agents in cutaneous irAEs.

Research Articles

Preclinical studies demonstrate that relatlimab specifically blocks the interaction between LAG-3 and its ligands. The data provide a biological rationale for combining relatlimab with the PD-1 antibody nivolumab as an effective cancer immunotherapeutic strategy.

Immuno-PET is a promising approach for noninvasively monitoring immune cells in the tumor microenvironment. This study reports the development of a fully human anti-CD8 that has excellent immuno-PET sensitivity and has potential for translation to clinical immunotherapy trials.

The tyrosine kinase inhibitor imatinib is shown to alter intratumoral CD8+ T-cell subtypes and antitumor activity in gastrointestinal stromal tumor. Combining T-cell agonistic therapy with imatinib improves antitumor responses in a mouse model of the disease.

Gastric dysbiosis, in particular higher Methylobacterium abundance, is associated with decreased CD8+ tissue-resident memory T cells. This results in gastric cancer immune evasion and poor prognosis, suggesting Methylobacterium may play a role in gastric carcinogenesis.

Expression of CIITA by tumor cells is required for the efficacy of BCG immunotherapy of bladder cancer but is not required for response to immune checkpoint blockade, suggesting that tumor characteristics may influence response to different modalities of immunotherapy for bladder cancer.

Melanoma is shown to acquire resistance to multiple lines of immunotherapy by gaining consecutive alterations that lead to pan T-cell immune escape, highlighting the complexity underlying immunoediting.

Myc-driven B-cell lymphoma is demonstrated to induce selective and early TCR-independent metabolic suppression of CD4+ T cells. This process precedes changes to T-cell fate and function and occurs before significant changes in tumor burden.

Close Modal

or Create an Account

Close Modal
Close Modal